Premium
Invasive pulmonary aspergillosis associated with COVID‐19 in a kidney transplant recipient
Author(s) -
Trujillo Hernando,
FernándezRuiz Mario,
Gutiérrez Eduardo,
Sevillano Ángel,
CaravacaFontán Fernando,
Morales Enrique,
LópezMedrano Francisco,
Aguado José María,
Praga Manuel,
Andrés Amado
Publication year - 2021
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13501
Subject(s) - medicine , immunosuppression , sputum , aspergillosis , aspergillus fumigatus , kidney transplantation , population , covid-19 , voriconazole , isolation (microbiology) , intensive care medicine , transplantation , immunology , disease , pathology , infectious disease (medical specialty) , tuberculosis , antifungal , dermatology , bioinformatics , environmental health , biology
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) might increase the risk of invasive pulmonary aspergillosis (IPA). Although several case reports and small series have been reported in the general population, scarce information is available regarding coronavirus disease 2019 (COVID‐19)‐associated IPA in the setting of solid organ transplantation. We describe a case of a kidney transplant recipient with severe COVID‐19 that was subsequently diagnosed with probable IPA on the basis of the repeated isolation of Aspergillus fumigatus in sputum cultures, repeatedly increased serum (1 → 3)‐β‐d‐glucan levels, and enlarging cavitary nodules in the CT scan. The evolution was favorable after initiation of isavuconazole and nebulized liposomal amphotericin B combination therapy and the withdrawal of immunosuppression.